Bookmark Article
The medicines watchdog in England and Wales has made a U-turn decision to offer a twice-a-day pill on the NHS to around 3,000 women with advanced breast cancer each year. Capivasertib, a game-changing treatment for hormone receptor (HR)-positive HER2-negative breast cancer with specific genetic mutations that has spread, has been hailed as a landmark moment by experts. This decision could greatly benefit women with this type of advanced breast cancer.
Full Article
